{
  "id": 19502968,
  "title": "VectorY bags $83.5M for antibody gene therapies in neurodegenerative diseases",
  "url": "https://urgent.news/2026/11/11/vectory-bags-83-5m-for-antibody-gene-therapies-in-neurodegenerative",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-11T13:00:05.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/vectory-bags-83-5m-for-antibody-gene-therapies-in-neurodegenerative-diseases/"
  },
  "original_language": "en",
  "account": null,
  "summary": "VectorY Therapeutics added €74.5 million ($83.5 million) to its Series A to fund a gene therapy that makes antibodies in the brain. The biotech’s lead asset VTx-002 is in a",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}